- About
-
Projects
-
Column 1
- Advancing Regulatory Science
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
-
Column 2
- Food & Nutrition
- Improving Access to FDA Information
- Research
- Substance Use Disorders
-
Column 1
- News and Events
- Expanded Access eRequest
Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.
The information provided here is drawn from ClinicalTrials.gov.
Emergency INDs
To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.
Search Tips
To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.
Displaying 220 of 530Castilla-La Mancha Health Service
Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)
Conditions: Covid-19 Infection
This is a multicenter, non-interventional, retrospective study using data captured in theEHRs (Electronic Health Records) of the participating hospital sites to determine factorsthat predict disease prognosis and outcomes in COVID-19 patients, specifically:Hospitalization/Off-site monitoring, transfer to ICU and/or need for medical mechanicalventilation (both invasive and non- invasive), length of ICU stay, and outcome (cure/hospital discharge, in-hospital death)
University of Kansas Medical Center
Conditions: COVID-19, SARS-CoV 2, Coronavirus, COVID
Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.
Lahore General Hospital
Conditions: COVID19
This study will define the kinetics of IgG responses to both N and S proteins in thesubjects who suffered from COVID 19 and then had recovered and those who were previouslyundiagnosed but were seropositive. These subjects will be followed for four months toevaluate the levels of antibodies in these people.
Imperial College London
Conditions: COVID-19, Pregnancy Related, Influenza, Human
The proposed study is designed to investigate if and how pregnant women infected withCoronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity. InDecember 2019, a group of people in Wuhan, China presented with symptoms of a pneumoniaof an unknown cause that led to the discovery of a new coronavirus called COVID-19.COVID-19 has caused a global pandemic with 7,140,000 confirmed cases and 418,000 deathsas of 13th June 2020. In the United Kingdom (UK), there have been 294,000 cases and41,662 deaths as of 13th June 2020. In humans, this infection primarily involves theupper part of the lungs, but it can also affect other organs. It causes mild symptoms inthe majority of people affected but some people can have severe infections, with someeven requiring critical care in hospital. During Severe acute respiratory syndrome(SARS), a previous coronavirus epidemic, pregnant women were disproportionately affectedwith severe illness. Understanding how the immune system responds long-term to thisinfection may hold the key to developing better vaccines and efficient treatment plans.Specialised immunity develops when individuals are infected by this and other viruses.The investigators of this study propose that, in pregnancy, this specialised immunity maynot behave effectively. This may affect their ability to develop long lasting immunityand make them more vulnerable to re-infection. In this study, the investigators aim torecruit patients across 6 groups including COVID-19 newly infected pregnant women, andpeople with differing illness severity, mild to moderate, severe/critical, no infection(controls), as well as pregnant women with influenza and those receiving influenzavaccine. The study team will compare COVID-19 in pregnancy with non-pregnant infected andwith influenza infected and vaccinated pregnant women. The study team will consentpatients in all of these groups to provide a series of blood samples at different timepoints in a 12-month period.
Istanbul Medipol University Hospital
Conditions: Lung Cancer, Physiotherapy
In this study, providing access to physiotherapy applications by telerehabilitationmethod and the effectiveness of this application will be examined for patients who haveundergone lung surgery in the early postoperative period during the pandemic process inwhich social isolation continues.
National Institute on Aging (NIA)
Conditions: COVID-19
Background:The higher death rate from COVID-19 in the older population is associated with low CD8 Tcell counts in the blood. Researchers want to learn the status of CD8 T cells specific toSARS-CoV-2 and their changes with aging and in COVID-19. This may help to identify whyCOVID-19 is particularly lethal in the elderly and help to create an effective vaccineagainst SARS-CoV-2 in the elderly.Objective:To identify SARS-CoV-2 specific CD8 T cells in humans, and to determine their quantityand quality in people who have recovered from COVID-19.Eligibility:Maryland residents age 18 and older who have tested positive for and recovered fromCOVID-19.Design:Participants will be screened by phone. They must be able to provide a copy of theirpositive COVID-19 test result.Participants will visit the NIA/Clinical Research Unit. The visit will take about 1 hour.Laboratory tests showing a positive COVID-19 result will be verified.Participants vital signs will be checked. This will include blood pressure, temperature,pulse, and respiration. Height and weight will be measured.Participants will have a medical history and medicine review. They will complete aCOVID-19 questionnaire.Participants will have blood drawn. They will give a urine sample.Participants will give a saliva sample. They will rinse their mouth with water. Afterabout 3 minutes, they will let saliva pool in the base of their mouth and then spit intoa sterile container.Participants may be asked if they would be willing to return for optional visits at about4 months and 1 year later. They will repeat the same laboratory sampling performed at thefirst visit....
National Cancer Institute (NCI)
Conditions: Covid-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
This is a phase I trial followed by a phase II randomized trial. The purpose of phase Istudy is the feasibility of treating patients with acute respiratory distress syndrome(ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stemcells (MSC). The purpose of the phase II trial is to compare the effect of MSC withstandard of care in these patients. MSCs are a type of stem cells that can be taken fromumbilical cord blood and grown into many different cell types that can be used to treatcancer and other diseases. The MSCs being used for infusion in this trial are collectedfrom healthy, unrelated donors and are stored and grown in a laboratory. Giving MSCinfusions may help control the symptoms of COVID-19 related ARDS.
Henry Ford Health System
Conditions: COVID19
The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detectan immune response in COVID-19 patients in the Henry Ford Health System (HFHS), bothduring hospitalization and over the following 12 months.
Assiut University
Conditions: COVID19
To evaluate the spectrum of comorbidities and complications and its impact on theclinical outcome in hospitalized patients with coronavirus disease 2019 (COVID-19).
Centre Hospitalier Universitaire, Amiens
Conditions: COVID19, TSH, Cortisol
The data obtained from Covid-19 infections seem to suggest that the immunogenesis ofCovid-19 could in some cases be the result of immune dysregulation. On the other hand,endocrine damage is possible at the tile of Covid-19 infection (mainly thyroid,adrenal,and hypothalamus). These disorders are autoimmune or linked to degeneration.The main objective is to assess the thyroid function (thyrotropic axis) as well as thecorticotropic adrenal function of patients who have had Copvid-19 pneumonia. Thesecondary objectives is to describe the pathophysiological mechanisms of pulmonary andvasculothrombotic involvement of Covid-19